4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board. At Johns Hopkins University, Diane Griffin is the Distinguished Service Professor, a professor of Medicine and Neurology at the School of Medicine, and the W. Harry Feinstone professor at the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. She has also been vice president of the U.S. National Academy of Sciences since

BOSTON, Sept. 16, 2021 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the appointment of Jennifer Raymond as SVP, CMC & Manufacturing today. Raymond joins GreenLight from GSK with more than 23 years of experience in the pharmaceutical industry, including 13 years in vaccines development, production, and Quality Assurance, across Merck, Novartis, and GSK. She has comprehensive first-hand experience in both R&D and Operations in small and large scale biological platforms (mammalian, viral, bacterial). Raymond's recent work includes development and launch of specialty biophar

BOSTON, Feb. 3, 2022 /PRNewswire/ -- GreenLight Biosciences ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (NASDAQ:ENVI) ("ENVI"), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination. In connection with the closing, the company changed its name to GreenLight Biosciences Holdings, public-benefit corporation, with shares of Class A common stock and public warrants

BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ:ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination with Greenlight Biosciences was approved in a shareholder vote held yesterday, with 80.7% of shareholders participating in the vote and 78.6% voting in favor of the combination. Subject to the satisfaction or waiver of the other customary closing conditions, Environmental Impact Acquisition Corp. anticipates closing the business combination today. In connection with the closing, the

BOSTON, Jan. 31, 2022 /PRNewswire/ -- GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions. Through the partnership, the two companies will explore synergies between Germains' seed priming and coating technologies and GreenLight's dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops

BOSTON, Jan. 28, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation ("ENVI" or the "Company") (NASDAQ:ENVI) today announced that it had achieved a quorum for the special meeting of its shareholders to be held on February 1, 2022 (the "Special Meeting"), in connection with its business combination with GreenLight Biosciences Inc. ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture. ENVI's shareholders who have submitted proxies to date on the proposals included in

BOSTON, Jan. 14, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ:ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitive proxy statement/prospectus (the "Proxy Statement") relating to the previously announced business combination with GreenLight Biosciences, Inc. ("GreenLight"), a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, has been filed with the U.S. Securities and Exchange Commission (the "SEC") on January 13, 2022. ENVI has comme

BOSTON, Jan. 7, 2022 /PRNewswire/ -- GreenLight Biosciences, a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced the expansion of its research and development operations in Research Triangle Park (RTP), North Carolina. The new greenhouse, laboratory, and offices will add more than 60,000 square feet of space and enable the continuing growth of GreenLight's plant health pipeline, adding more jobs in the process.  "This additional capacity is a critical step in helping us capitalize on our solutions for

BOSTON and NEW YORK, Dec. 3, 2021 /PRNewswire/ -- GreenLight Biosciences (ENVI) and IAVI, a nonprofit scientific research organization, today announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant. "The highly mutated Omicron variant may be partially capable of eluding existing vaccines, so rapid adaptation is an urgent priority," said GreenLight CEO Andrey Zarur. "We have started lab work already. We will be testing a new candidate vaccine shortly in preclinical models. We have also begun an analysis on how we would proceed in clinical stu

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and its partners were among the first to conduct HIV vaccine clinical trials in Africa, and since then, IAVI has sponsored more than 60 vaccine and biologics clinical trials in 13 countries. IAVI has built partnerships with centers of excellence for clinical research in five sub-Saharan African countries, and is developing vaccines and biologics against HIV, COVID-19, tuberculosis, Lassa fever, snakebite, and other diseases.

BOSTON and INCHEON, South Korea, Nov. 24, 2021 /PRNewswire/ -- GreenLight Biosciences (NASDAQ:ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services, announced a partnership agreement in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale. The partnership aims to accelerate production of GreenLight's COVID-19 vaccine candidate for Phase III clinical trial

BOSTON, Nov. 23, 2021 /PRNewswire/ -- GreenLight Biosciences Inc., an RNA-focused biotech ("GreenLight"), and Environmental Impact Acquisition Corp. (NASDAQ:ENVI) today announced an expansion of its PIPE financing to an aggregate $124 million in gross proceeds. The expanded financing includes a $10 million strategic investment from Serum Life Sciences Ltd ("Serum Life Sciences"), a subsidiary of Serum Institute of India Pvt. Ltd. (the "Serum Institute"). The world's largest vaccine manufacturer by volume, the Serum Institute sells more than 1.5 billion doses to over 160 countr

 GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions. Through the partnership, the two companies will explore synergies between Germains' seed priming and coating technologies and GreenLight's dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops. In October 2021, GreenLight announced that the company had achieved, for the first time ever, effective field control of fungal pathogens using doubl

Upon consummation of the business combination, the ENVI ticker will transition to "GRNA" and is expected to start trading on the Nasdaq on February 3, 2022 BOSTON, Jan. 28, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation ("ENVI" or the "Company") (NASDAQ:ENVI) today announced that it had achieved a quorum for the special meeting of its shareholders to be held on February 1, 2022 (the "Special Meeting"), in connection with its business combination with GreenLight Biosciences Inc. ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture. ENVI's shareholders who have submitted pr

Environmental Impact Acquisition Corporation (NASDAQ:ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitive proxy statement/prospectus (the "Proxy Statement") relating to the previously announced business combination with GreenLight Biosciences, Inc. ("GreenLight"), a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, has been filed with the U.S. Securities and Exchange Commission (the "SEC") on January 13, 2022. ENVI has commenced mailing of the Proxy Statement and a notice and voting instruction form or a proxy card relating to the special meeting of ENVI stockholders (the

GreenLight Biosciences, a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced the expansion of its research and development operations in Research Triangle Park (RTP), North Carolina. The new greenhouse, laboratory, and offices will add more than 60,000 square feet of space and enable the continuing growth of GreenLight's plant health pipeline, adding more jobs in the process.  "This additional capacity is a critical step in helping us capitalize on our solutions for agriculture to realize a food-secure future," says Mark Singleton, head of plant health at RTP. "The investment will help to keep us at the cutting e

GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and its partners were among the first to conduct HIV vaccine clinical trials in Africa, and since then, IAVI has sponsored more than 60 vaccine and biologics clinical trials in 13 countries. IAVI has built partnerships with centers of excellence for clinical research in five sub-Saharan African countries, and is developing vaccines and biologics against HIV, COVID-19, tuberculosis, Lassa fever, snakebite, and other diseases. This partnership will help advance GreenLight's mRNA COVID-19 vaccine candidate. More vaccines to prevent COVID-

GreenLight Biosciences (NASDAQ:ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services, announced a partnership agreement in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale. The partnership aims to accelerate production of GreenLight's COVID-19 vaccine candidate for Phase III clinical trials and, subject to regulatory approval, commercial sales. The co

GreenLight Biosciences Inc., an RNA-focused biotech ("GreenLight"), and Environmental Impact Acquisition Corp. (NASDAQ:ENVI) today announced an expansion of its PIPE financing to an aggregate $124 million in gross proceeds. The expanded financing includes a $10 million strategic investment from Serum Life Sciences Ltd ("Serum Life Sciences"), a subsidiary of Serum Institute of India Pvt. Ltd. (the "Serum Institute"). The world's largest vaccine manufacturer by volume, the Serum Institute sells more than 1.5 billion doses to over 160 countries; this includes national immunization programs and vaccines addressing polio, diphtheria, tetanus, pertussis, Hib, BCG, r-Hepatitis B, measles, mump

SC 13G - Environmental Impact Acquisition Corp (0001822691) (Subject)

425 - Environmental Impact Acquisition Corp (0001822691) (Subject)

8-K - Environmental Impact Acquisition Corp (0001822691) (Filer)

425 - Environmental Impact Acquisition Corp (0001822691) (Subject)

425 - Environmental Impact Acquisition Corp (0001822691) (Subject)

EFFECT - Environmental Impact Acquisition Corp (0001822691) (Filer)

424B3 - Environmental Impact Acquisition Corp (0001822691) (Filer)

S-4/A - Environmental Impact Acquisition Corp (0001822691) (Filer)

S-4/A - Environmental Impact Acquisition Corp (0001822691) (Filer)

8-K/A - Environmental Impact Acquisition Corp (0001822691) (Filer)

425 - Environmental Impact Acquisition Corp (0001822691) (Subject)